Weekly injection of histaglobulin produces long-term remission in chronic urticaria: A prospective clinical study

Abstract

Objective:Treatment of chronic urticaria (CU) can be difficult in many patients. Achieving long-term remission and reducing the requirement of antihistamines are vital in CU. The objective of this study was to assess the effectiveness of injection histaglobulin, a complex of histamine and human immunoglobulin, in producing relief in patients with CU.Materials and Methods:Fifty-one patients with CU were enrolled into this prospective clinical study. Patients were administered 1 ml of injection histaglobulin subcutaneous for 8 consecutive weeks. They were also prescribed tablet levocetirizine 5 mg to be taken when required (but not more than the permitted dosage). Efficacy was assessed using urticaria activity score (UAS) which has a maximum score of 33/day, during each weekly visit. Final assessment was done after 24 weeks.Results:Twenty-nine patients had completed the entire 8-week drug regimen. Mean basal UAS was 18.9 ± 6.3 and it reduced to 80.4% by 8 weeks. The angioedema sub-score reduced by 89.8%. Anti-histamine pill burden also reduced significantly. By 24 weeks of starting the therapy, 23 patients (45%) had attained complete remission. No adverse effects to the drug were observed.Conclusions:Histaglobulin was found to be effective in producing long-term remission and it reduced the antihistamine requirement as well. Thus, it can serve as an effective alternative to existing treatment modalities.

Induction of Remission in Chronic Urticaria by Immunotherapy Using Immunoglobulin/histamine Complex (HistobulinTM): A Case Report

“…In the previous treatment using immunoglobulin/histamine complex, the duration of treatment accordingly the numbers of treatment was xed and the clinical results were evaluated. Fortunately, remission was observed in some patients in another previous report [17], and the possibility that the immunoglobulin/histamine complex induces remission in CSU was suspected. In this study, Histobulin™ treatment continued, and remission was induced in all 4 cases of CSU.…”

“…The major points of this report are that remission was achieved by Histobulin™ in CSU and that Histobulin™ was effective. Despite the results that remission was observed in some patients in a previous report [17], in this trial, the new concept was applied which consisted of continuing Histobulin™ treatment until remission was induced, rather than xing the treatment frequency and period. The frequency of injection that led to the actual clinical improvement in a patient was 30 times that of injection in one case (Table 1a, Fig.…”

“…Immunoglobulin/histamine complexes have been reported to be effective in chronic urticaria for several decades without su cient reports [16][17][18]. In a recent report, some patients showed remission, and the remission of chronic urticaria by Histobulin™ treatment was the focus [17].…”

Immunotherapy Using HistobulinTM In Psoriasis: A Case Report

“…Histobulin™ (Green Cross PD, Korea) is a histamine-xed immunoglobulin preparation comprising 0.15 µg of histamine dihydrochloride and 12 mg of IgG [6]. This preparation was developed for the regulation of blood serum levels by histaminopexy effects [7] and has been known to be effective in treating patients with allergic rhinitis, bronchial asthma, chronic urticaria and atopic dermatitis (AD) [8][9][10][11]. In this report, a case of a psoriasis patient who achieved complete remission with Histobulin™ was described.…”

Induction of remission in chronic urticaria by immunotherapy using immunoglobulin/histamine complex (Histobulin™): a case report

“…Immunoglobulin/histamine complexes have been reported to be effective in chronic urticaria for several decades without sufficient reports [ 16 – 18 ]. In a recent report, some patients showed remission, and the remission of chronic urticaria by Histobulin™ treatment was the focus [ 17 ]. In this report, Histobulin™ therapy was continued until remission was induced, which is a new therapeutic approach.…”